MD Magazine: Specialty: Ophthalmology Copyright (c) 2017 Intellisphere, LLC. All rights reserved. http://www.mdmag.com/specialty/ophthalmology/rss Ophthalmology en-us Wed, 23 Aug 2017 04:08:12 UTC Aflibercept Aids Visual Acuity in PROMISE Study http://www.mdmag.com/conference-coverage/asrs-2017/aflibercept-aides-visual-acuity-in-promise-study Tue, 15 Aug 2017 23:06:00 UTC Unapproved Stem Cell Therapies Are Causing "Dismal" Health Outcomes http://www.mdmag.com/conference-coverage/asrs-2017/unapproved-stem-cell-therapies-are-causing-dismal-health-outcomes Tue, 15 Aug 2017 22:22:00 UTC Fewer Ranibizumab Doses OK for mCNV http://www.mdmag.com/conference-coverage/asrs-2017/fewer-ranibizumab-doses-ok-for-mcnv Tue, 15 Aug 2017 22:02:00 UTC Aflibercept Delivers Dynamic Vascular Changes in DME, RVO http://www.mdmag.com/conference-coverage/asrs-2017/aflibercept-induces-dynamic-vascular-changes-in-dme-rvo Tue, 15 Aug 2017 18:06:00 UTC Novel Device Could Represent New Endpoint in Clinical Trials for Visual Function http://www.mdmag.com/conference-coverage/asrs-2017/novel-device-could-represent-new-endpoint-in-clinical-trials-for-visual-function Mon, 14 Aug 2017 19:54:00 UTC Sirolimus/Aflibercept Combo Shows Potential Benefits for Wet AMD http://www.mdmag.com/conference-coverage/asrs-2017/sirolimus-aflibercept-combo-shows-potential-benefits-for-wet-amd Mon, 14 Aug 2017 19:23:00 UTC OPT-302 Meets Phase 1/2A Endpoints as Pan-VEGF Inhibitor for nAMD http://www.mdmag.com/conference-coverage/asrs-2017/opt302-meets-phase-12a-endpoints-as-panvegf-inhibitor-for-namd Mon, 14 Aug 2017 18:13:00 UTC Aflibercept Similar to Ranibizumab in Visual Acuity Improvements in VIEW Studies http://www.mdmag.com/conference-coverage/asrs-2017/aflibercept-similar-to-ranibizumab-in-visual-acuity-improvements-in-view-studies Mon, 14 Aug 2017 16:23:00 UTC ICON-1 Plus Ranibizumab Shows Promise for Wet AMD http://www.mdmag.com/conference-coverage/asrs-2017/icon1-plus-ranibizumab-shows-promise-for-wet-amd Mon, 14 Aug 2017 16:05:00 UTC Intravitreal Sirolimus Lowers Vitreous Haze Scores, Tapers Corticosteroid Use in SAKURA Study http://www.mdmag.com/conference-coverage/asrs-2017/intravitreal-sirolimus-lowers-vitreous-haze-scores-tapers-corticosteroid-use-in-sakura-study Sun, 13 Aug 2017 18:58:00 UTC Bevacizumab Could Prevent Retina Re-Detachment After PPV http://www.mdmag.com/conference-coverage/asrs-2017/bevacizumab-could-prevent-retina-redetachment-after-ppv Sun, 13 Aug 2017 17:15:00 UTC Adalimumab Superior to Placebo Across Uveitis Idiopathic Etiologies http://www.mdmag.com/conference-coverage/asrs-2017/adalimumab-superior-to-placebo-across-uveitis-idiopathic-etiologies Sun, 13 Aug 2017 15:52:00 UTC Real-World Anti-VEGF DME Data Differ from Randomized Results http://www.mdmag.com/conference-coverage/asrs-2017/real-world-anti-vegf-dme-data-differ-from-randomized-results Sun, 13 Aug 2017 15:50:00 UTC C3F8 Superior to SF6 and Air in Treatment of Vitreomacular Traction http://www.mdmag.com/conference-coverage/asrs-2017/c3f8-superior-to-sf6-and-air-in-treatment-of-vitreomacular-traction Sat, 12 Aug 2017 18:31:00 UTC Severe Diabetic Retinopathy Leads to Higher Rate of Visual-Function Issues http://www.mdmag.com/medical-news/severe-diabetic-retinopathy-leads-to-higher-rate-of-visualfunction-issues Fri, 28 Jul 2017 09:00:00 UTC AMD Diagnoses Aided By Deep Learning Programs http://www.mdmag.com/medical-news/amd-diagnoses-aided-by-deep-learning-programs Tue, 25 Jul 2017 15:42:00 UTC AbbVie's HUMIRA Gets Positive Outlook from EMA http://www.mdmag.com/medical-news/abbvies-humira-gets-positive-outlook-from-ema Fri, 21 Jul 2017 14:41:00 UTC FDA Accepts Application for Potential First Gene Therapy for Genetic Disease in US http://www.mdmag.com/medical-news/fda-accepts-application-for-potential-first-gene-therapy-for-genetic-disease-in-us Mon, 17 Jul 2017 17:25:00 UTC Biomarkers for Inflammation May Help Identify Risk for AMD http://www.mdmag.com/medical-news/biomarkers-for-inflammation-may-help-identify-risk-agerelated-macular-degeneration Mon, 17 Jul 2017 16:40:00 UTC In Treatment-Resistant AMD, Contrast Sensitivity Improved after Switch from Ranibizumab to Aflibercept http://www.mdmag.com/medical-news/in-treatmentresistant-amd-contrast-sensitivity-improved-after-switch-from-ranibizumab-to-aflibercept- Thu, 13 Jul 2017 13:00:41 UTC Oral Drug X-82 Shows Promise for Wet Age-Related Macular Degeneration http://www.mdmag.com/medical-news/oral-drug-x82-shows-promise-for-wet-agerelated-macular-degeneration Mon, 10 Jul 2017 19:45:54 UTC Brolucizumab Meets Endpoints in Phase III Trials http://www.mdmag.com/medical-news/brolucizumab-meets-endpoints-in-phase-iii-trials Tue, 20 Jun 2017 13:58:50 UTC FDA Approves Allergic Conjunctivitis Treatment Zerviate http://www.mdmag.com/medical-news/fda-approves-allergic-conjunctivitis-treatment-zerviate Wed, 31 May 2017 01:55:00 UTC Study Finds 25% of Patients with AMD Remain Undiagnosed After Dilated Eye Exam http://www.mdmag.com/medical-news/study-finds-25-of-patients-with-amd-remain-undiagnosed-after-dilated-eye-exam Tue, 23 May 2017 07:17:00 UTC At-Risk Drivers Can Be Identified by Visual, Cognitive Acuity http://www.mdmag.com/conference-coverage/arvo-2017/at-risk-drivers-can-be-identified-by-visual-cognitive-acuity Fri, 12 May 2017 07:42:00 UTC Seeing into the Future Collaborative Care to Maintain Eye Health in Patients with Diabetes http://www.mdmag.com/conference-coverage/pri-med-west-2017 /seeing-into-the-future-collaborative-care-to-maintain-eye-health-in-patients-with-diabetes Fri, 12 May 2017 06:21:00 UTC New Baseline Models of DR Prediction Emerge at ARVO http://www.mdmag.com/conference-coverage/arvo-2017/new-baseline-models-of-dr-prediction-emerge-at-arvo Thu, 11 May 2017 07:46:00 UTC Study: Eating Fish Protects Against Diabetic Retinopathy in Asians http://www.mdmag.com/conference-coverage/arvo-2017/study-eating-fish-protects-against-diabetic-retinopathy-in-asians Thu, 11 May 2017 05:22:00 UTC Many With Diabetic Retinopathy Going Unscreened, Undiagnosed http://www.mdmag.com/conference-coverage/arvo-2017/mapping-diabetic-retinopathy-risk-could-improve-screening Wed, 10 May 2017 08:49:00 UTC Aflibercept Vs. Ranibizumab: Similar QOL Benefits, Varied Costs for Treating Diabetic Macular Edema http://www.mdmag.com/conference-coverage/arvo-2017/aflibercept-vs-ranibizumab-similar-qol-benefits-varied-costs-for-treating-diabetic-macular-edema Wed, 10 May 2017 07:08:00 UTC